ClinicalTrials.gg
Drug

Olutasidenib clinical trials

Also written Rezlidhia and FT-2102.

studies test it
16
open now
12
in phase 3
0
first study started
2016

How each study uses olutasidenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the olutasidenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 Dec 2022 · REZLIDHIA · NDA 215814 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Olutasidenib
13
IDH1-R132 Inhibitor FT-2102
4

Brand

Rezlidhia
5

Development codes

FT-2102
5

Studies by the year they started

16 studies that test it; most in 2026 (6)

Studies that test olutasidenib, by start year
YearStudies
20161
20181
20245
20253
20266

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
13
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 5 · Other 11

M.D. Anderson Cancer Center (5) · Forma Therapeutics, Inc. (2) · National Cancer Institute (NCI) (2) · Rigel Pharmaceuticals (2) · University of California, Davis (1) · Timothy Pardee (1) · City of Hope Medical Center (1) · Kissei Pharmaceutical Co., Ltd. (1)

Often tested with

Tested in the same studies.

Venetoclax (4) · Azacitidine (3) · Decitabine and cedazuridine drug combination (2) · Ziftomenib (1) · Busulfan (1) · Cytarabine (1) · Daunorubicin (1) · CA-4948 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5

Studies that test olutasidenib.

Studies

Open first, then newest update. How each study uses olutasidenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 16

Given beside what is tested · 1 — olutasidenib is usual care or a partner of the new treatment

Codes

What other systems call olutasidenib · ClinicalTrials.gg INT001407

  • MeSH (NLM) C000710173olutasidenibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 0T4IMT8S5ZOLUTASIDENIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2623641One source FDA
  • Wikidata Q76854304olutasidenibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C129687OlutasidenibOne source FDA
  • DrugBank DB16267One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.